自体脐带血输注治疗 1 型糖尿病患儿未能保留 C 肽。
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.
机构信息
Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
出版信息
Diabetes Care. 2011 Dec;34(12):2567-9. doi: 10.2337/dc11-1406. Epub 2011 Oct 19.
Abstract
OBJECTIVE
We conducted an open-label, phase I study using autologous umbilical cord blood (UCB) infusion to ameliorate type 1 diabetes (T1D). Having previously reported on the first 15 patients reaching 1 year of follow-up, herein we report on the complete cohort after 2 years of follow-up.
RESEARCH DESIGN AND METHODS
A total of 24 T1D patients (median age 5.1 years) received a single intravenous infusion of autologous UCB cells and underwent metabolic and immunologic assessments.
RESULTS
No infusion-related adverse events were observed. β-Cell function declined after UCB infusion. Area under the curve C-peptide was 24.3% of baseline 1 year postinfusion (P < 0.001) and 2% of baseline 2 years after infusion (P < 0.001). Flow cytometry revealed increased regulatory T cells (Tregs) (P = 0.04) and naive Tregs (P = 0.001) 6 and 9 months after infusion, respectively.
CONCLUSIONS
Autologous UCB infusion in children with T1D is safe and induces changes in Treg frequency but fails to preserve C-peptide.
摘要
目的
我们进行了一项开放性、I 期研究，使用自体脐带血（UCB）输注来改善 1 型糖尿病（T1D）。先前我们报告了前 15 名达到 1 年随访的患者，在此我们报告了 2 年随访后的完整队列。
研究设计和方法
共 24 名 T1D 患者（中位年龄 5.1 岁）接受单次静脉输注自体 UCB 细胞，并进行代谢和免疫评估。
结果
未观察到输注相关不良事件。UCB 输注后β细胞功能下降。输注后 1 年 C 肽曲线下面积为基线的 24.3%（P<0.001），输注后 2 年为基线的 2%（P<0.001）。流式细胞术显示，输注后 6 个月和 9 个月分别分别增加了调节性 T 细胞（Tregs）（P=0.04）和幼稚 Tregs（P=0.001）。
结论
在 T1D 儿童中自体 UCB 输注是安全的，并诱导 Treg 频率发生变化，但未能保留 C 肽。
相似文献
1
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.自体脐带血输注治疗 1 型糖尿病患儿未能保留 C 肽。
Diabetes Care. 2011 Dec;34(12):2567-9. doi: 10.2337/dc11-1406. Epub 2011 Oct 19.
2
Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.自体脐带血输注治疗 1 型糖尿病的非常年幼的儿童。
Diabetes Care. 2009 Nov;32(11):2041-6. doi: 10.2337/dc09-0967.
3
Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.自体脐带血输注联合口服二十二碳六烯酸和维生素 D 补充剂以保存 1 型糖尿病患儿的 C 肽。
Biol Blood Marrow Transplant. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20.
4
Autologous umbilical cord blood infusion for type 1 diabetes.自体脐带血输注治疗1型糖尿病
Exp Hematol. 2008 Jun;36(6):710-5. doi: 10.1016/j.exphem.2008.01.009. Epub 2008 Mar 20.
5
Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial.单次自体脐血输注对新发 1 型糖尿病患儿胰岛β细胞和免疫功能的影响：一项非随机对照试验。
Pediatr Diabetes. 2014 Mar;15(2):100-9. doi: 10.1111/pedi.12072. Epub 2013 Sep 19.
6
Use of a precious resource: parental decision making about using autologous umbilical cord blood in studies involving young children with type 1 diabetes.宝贵资源的利用：父母在涉及 1 型糖尿病幼儿的研究中决定使用自体脐带血的决策。
Contemp Clin Trials. 2011 Jul;32(4):524-9. doi: 10.1016/j.cct.2011.04.004. Epub 2011 Apr 17.
7
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.低剂量白细胞介素 2 和调节性 T 细胞过继细胞疗法在 1 型糖尿病患者中的作用。
JCI Insight. 2021 Sep 22;6(18):e147474. doi: 10.1172/jci.insight.147474.
8
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells.通过脐带血来源的多能干细胞的免疫调节实现胰岛 β 细胞再生，从而逆转 1 型糖尿病。
BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.
9
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.一项自体多克隆扩增调节性 T 细胞治疗新发 1 型糖尿病儿童的 2 期随机试验。
Sci Transl Med. 2024 May 8;16(746):eadn2404. doi: 10.1126/scitranslmed.adn2404.
10
Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion.脐带间质基质干细胞联合自体骨髓单个核细胞移植治疗 1 型糖尿病：一项评估安全性和对胰岛素分泌影响的开放性、随机对照临床研究。
Diabetes Care. 2016 Jan;39(1):149-57. doi: 10.2337/dc15-0171. Epub 2015 Dec 1.
引用本文的文献
1
Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.脐带血衍生细胞扩增：一种有潜力的神经保护治疗方法。
Stem Cell Res Ther. 2024 Jul 29;15(1):234. doi: 10.1186/s13287-024-03830-0.
2
Human Hematopoietic Stem/Progenitor Cells in Type One Diabetes Mellitus Treatment: Is There an Ideal Candidate?人源造血干/祖细胞在 1 型糖尿病治疗中的应用：是否存在理想的候选细胞？
Cells. 2023 Mar 30;12(7):1054. doi: 10.3390/cells12071054.
3
Umbilical cord mesenchymal stromal cells transplantation delays the onset of hyperglycemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes through multiple immunosuppressive and anti-inflammatory responses.在实验性自身免疫性糖尿病的RIP-B7.1小鼠模型中，脐带间充质基质细胞移植通过多种免疫抑制和抗炎反应延缓了高血糖的发生。
Front Cell Dev Biol. 2023 Feb 15;11:1089817. doi: 10.3389/fcell.2023.1089817. eCollection 2023.
4
Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis.研究造血和间充质干细胞移植治疗 T1DM 的安全性和有效性：系统评价和荟萃分析。
Syst Rev. 2022 May 2;11(1):82. doi: 10.1186/s13643-022-01950-3.
5
High Integrity and Fidelity of Long-Term Cryopreserved Umbilical Cord Blood for Transplantation.长期冷冻保存的脐带血用于移植的高完整性和高保真度。
J Clin Med. 2021 Jan 14;10(2):293. doi: 10.3390/jcm10020293.
6
Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study.脐带间充质干细胞治疗糖尿病的疗效：一项荟萃分析研究。
Stem Cell Res Ther. 2020 Nov 16;11(1):484. doi: 10.1186/s13287-020-01996-x.
7
Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?基于细胞的 1 型糖尿病治疗：我们是否应该考虑高血糖？
Front Immunol. 2019 Feb 5;10:79. doi: 10.3389/fimmu.2019.00079. eCollection 2019.
8
The Future State of Newborn Stem Cell Banking.新生儿干细胞库的未来状况
J Clin Med. 2019 Jan 18;8(1):117. doi: 10.3390/jcm8010117.
9
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits.糖尿病患者的干细胞治疗：基于代谢组学的风险与益处的系统评价和荟萃分析
Stem Cell Investig. 2018 Nov 14;5:40. doi: 10.21037/sci.2018.11.01. eCollection 2018.
10
Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis.干细胞移植治疗1型糖尿病患者：一项荟萃分析。
Exp Ther Med. 2018 Dec;16(6):4479-4492. doi: 10.3892/etm.2018.6769. Epub 2018 Sep 19.
本文引用的文献
1
Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.通过细胞动员进行免疫耗竭可赋予免疫调节作用，并逆转非肥胖糖尿病小鼠的自身免疫性糖尿病。
Diabetes. 2009 Oct;58(10):2277-84. doi: 10.2337/db09-0557. Epub 2009 Jul 23.
2
The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.糖尿病患者的效应T细胞对通过CD4+FOXP3+调节性T细胞进行的调节具有抗性。
J Immunol. 2008 Nov 15;181(10):7350-5. doi: 10.4049/jimmunol.181.10.7350.
3
Autologous umbilical cord blood infusion for type 1 diabetes.自体脐带血输注治疗1型糖尿病
Exp Hematol. 2008 Jun;36(6):710-5. doi: 10.1016/j.exphem.2008.01.009. Epub 2008 Mar 20.
4
Treg in type 1 diabetes.1型糖尿病中的调节性T细胞
Cell Biochem Biophys. 2007;48(2-3):165-75. doi: 10.1007/s12013-007-0018-5.
5
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.1型糖尿病中FOXP3 +调节性T细胞频率无改变。
Diabetes. 2007 Mar;56(3):604-12. doi: 10.2337/db06-1248.
6
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.1型糖尿病中CD4+ CD25+ T细胞的功能缺陷及年龄对其频率的影响
Diabetes. 2005 May;54(5):1407-14. doi: 10.2337/diabetes.54.5.1407.
Zotero 插件